Antibodies as specific tumor therapeutic agents: A dream or reality?;Antikorper als spezifische Tumortherapeutika. Wunschtraum oder Realitat?

Internist

Volumn 38, Issue 11, 1997, Pages 1055-1062

  Gramatzki, M ^a,b   Valerius, T ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; ANTIBODY; ANTIBODY CONJUGATE;

APOPTOSIS; CANCER; HUMAN; REVIEW; ANIMAL; ANTIBODY SPECIFICITY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOLECULAR CLONING; MOUSE; NEOPLASM; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLONING, MOLECULAR; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; NEOPLASMS; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0031261854     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050117     Document Type: Review

References (51)

1. Ehrlich P (1900) On immunity with special reference to cell life. Proc Royal Soc London 66:424-448
2. Köhler G, Milstein C (1975) Continuous cultures of fused cells producing antibodies to predefined specificity. Nature 256:495-497
3. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (1993) Leukocyte Typing V. Oxford University Press, Oxford
4. Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, von dem Borne AEGKr, Zola H (1997) Update of CD antigens, 1996. J Immunol 158:3035-3036
5. Reichmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323-327
6. Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Valerius T, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, Van de Winkel JGJ (1997) FcαRI (CD89) as a novel trigger molecule for bispecific antibodies. Blood (im Druck)
7. Marks C, Marks JD (1996) Phage libraries - a new route to clinically useful antibodies. N Engl J Med 335:730-733
8. Gramatzki M, Burger R, Strobel G, Trautmann U, Bartram CR, Helm G, Horneff G, Alsalameh S, Jonker M, Gebhart E, Kalden JR (1995) Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia 9:382-390
9. Baum W, Steininger H, Bair HJ, Becker W, Hansen-Hagge TE, Kressel M, Kremmer E, Kalden JR, Gramatzki M (1996) Therapy with monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. British J Haematol 95:327-338
10. Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515
11. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878
12. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase 1 clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466
13. McLaughlin P, Grillo-Lopez AJ, Czuczman M, Link BK, Davis TA, Dillman RO, Ho AD, Bennett JM, Heyman MR, Schilder RJ, Cabanillas F, Dallaire BK, White CA (1997) IDEC-C2B8 (rituximab): clinical activity in clinically chemoresistant (CCRD) low-grade or follicular lymphoma (LG/F NHL) and in patients (pts) relapsing after anthracycline therapy (ANTHRA-RX) or ABMT. Proc Am Soc Clin Oncol 16:16a
14. Baselga J, Tripathy D, Mendelson J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman, AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson C, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744
15. Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910-5913
16. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 343:1177-1183
17. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, England R, Horak E, Mishra B, Dipre M, Hale P, Fleisher TA, Junghans RP, Jaffe ES, Nelson DL (1993) The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus 1 induced adult T-cell leukemia. Blood 82:1701-1712
18. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B (1995) Biologic Effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86:685-691
19. Deo YM, Graziano RF, Repp R, Van de Winkel JGJ (1997) Clinical significance of IgG receptors and FcγR-directed immunothérapies. Immunol today 18:127-135
20. Weiner GJ, DeGast GC (1995) Bispecific monoclonal antibody therapy of B-cell malignancy. Leukemia Lymphoma 16:199-207
21. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042-2047
22. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW (1995) Phase 1a/1 b trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281-2292
23. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, Van de Winkel JGJ (1993) Involvement of the high affinity receptor for IgG (FcγRI;CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931-939
24. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, Van de Winkel JGJ (1997) Preclinical studies with FcγR bispecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696-701
25. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JGJ, Lang N, Kalden JR (1995) G-CSF stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcγRI and to HER-2/neu (MDX 210). J Hematotherapy 4:415-421
26. Vallera DA (1994) Immunotoxins: will their clinical promise be fulfilled? Blood 83:309-317
27. Wilder RB, DeNardo GL, DeNardo SJ (1996) Radioimmunotherapy: recent results and future directions. J Clin Oncol 14:1383-1400
28. Koch B, Baum W, Beck E, Eger G, Rohwer P, Kalden JR, Gramatzki M (1991) In vitro activity of immunoconjugates between cis-platinum and monoclonal antibodies. Antibody Immunocon Radiopharm 4:121-132
29. Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, Smith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellstrom KE, Hellstrom I (1997) Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res 57:100-105
30. Elias DJ, Kline LE, Robbins BA, Johnson HCjr, Pekny K, Benz M, Robb JA, Walker LE, Kosty M, Dillman RO (1994) Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med 150:1114-1122
31. Sievers EL, Bernstein ID, Spielberger RT, Forman SJ, Berger MS, Shannon-Dorcy K, Appelbaum FR (1997) Dose escalation phase 1 study of recombinant engineered human anti-CD33 antibody-calicheamycin drug conjugate (CMA 676) in patients with relapsed or refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 16:3a
32. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Dralesk J, Fishwild D, Scannon P, Byers V (1991) Phase 1 trial of H65-RTA immunotoxin in patients with cutaneous T-cell lymphoma. Blood 78:1173-1182
33. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, Nadler LM (1993) Anti-B4-blocked ricin: a phase 1 trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726-737
34. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES (1993) A phase 1 study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-2633
35. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E (1997) A phase-1 study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403-410
36. Gribben JG, Nadler LM (1996) Purging of malignant cells. In: Morstyn G, Sheridan W (Hrsg) Cell Therapy. Cambridge University Press, Cambridge, S 250-266
37. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, Badger CC, Storb R, Nelp WB, Bernstein ID (1995) Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-1131
38. Brown S, Miller RA, Horning SJ, Czerwinski DK, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651-661
39. Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, Cornbleet JA, Levy R (1996) Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87:893-899
40. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA (1994) A Phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immonogenicity. Blood 83:1760-1768
41. Dyer MJS, Hale G, Hayhoe FGJ, Waldman H (1989) Effects of CAMPATH-1 antibodies in vivo and in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431-1439
42. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193
43. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graft, WT, The TH, de Leij L, Mulder NH (1994) Phase 1 study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. British J Cancer 70:652-661
44. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, Moon S, Scott P, Miller RA, Wahl RL (1992) Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696-1711
45. Press OW, Eary JF, Appelbaum FR, Martin PJ, NeIp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID (1995) Phase 2 trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 346:336-340
46. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981
47. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Hansen HJ, Shevitz J, Leung S, Rubin AD, Herskovic T, Hanley D, Goldenberg DM (1995) Treatment of Non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55 (23 Suppl): 5899s-5907s
48. DeNardo GL, Lewis JR DeNardo SJ, O'Grady LF (1993) Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425-1432
49. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Bechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, Top LE, Bamford R, Zaknoen S, Roessler E, Kasten-Sportes C, England R, Litou H, Johnson JA, Jackson-White T, Manns A, Hanchard B, Junghans RP, Nelson DL (1995) Radioimmunotherapy of interleukin-2 Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86:4063-4075
50. Jurcic JG, Caron PC, Miller WH, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell RP, Scheinberg DA (1995) Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 9:244-248
51. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, St. Germain J, Carswell Richards E, Larson SM, Oettgen HF, Old LJ (1994) Phase I/II study of Iodine-131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12:1561-1571